Pimecrolimus permeates less than tacrolimus through normal, inflamed, or corticosteroid‐pretreated skin
- 1 August 2005
- journal article
- Published by Wiley in Experimental Dermatology
- Vol. 14 (10) , 752-757
Abstract
Abstract: The permeabilities of normal human and normal, inflamed, or corticosteroid (CS) pretreated skin of young domestic pigs for pimecrolimus and tacrolimus were compared in vitro, using Franz‐type diffusion cells. The test articles were either used as 1.0% solutions or as the marketed formulations (Elidel 1% cream, Protopic 0.1%, and 0.03% ointment). In normal human skin, the permeation rate of pimecrolimus from the 1% cream was about sixfold lower than that of tacrolimus from 0.1% ointment and by a factor of 4.3 lower compared with tacrolimus from Protopic 0.03%. In pigs, sodium laurylsulfate‐induced irritant contact dermatitis resulted in significantly faster skin permeation of both drugs from applied solutions. The permeation rate for pimecrolimus was lower than that for tacrolimus. Thus, at 24 h, pimecrolimus concentrations in the receptor fluid were 2.8‐fold lower than the tacrolimus levels. Compared with normal porcine skin, permeation of drugs through hydrocortisone (1.0%)‐, mometasone (0.1%)‐, or clobetasol‐17‐butyrate (0.05%)‐pretreated skin was increased by factors of 3.6 (pimecrolimus, applied as 1% cream) and 1.7 (tacrolimus, applied as 0.1% ointment). In normal pig skin, the permeation rate of tacrolimus was found to be 11.2 times higher than that of pimecrolimus and 3.5‐ to 7.1‐fold higher in CS‐pretreated skin, independent of the potency of the CSs. The present in vitro data suggest that in patients with acute skin inflammation or after therapy with topical CSs, percutaneous absorption and, as a consequence, systemic drug exposure will be lower with Elidel 1% cream as compared with Protopic 0.1% and 0.03% ointment.Keywords
This publication has 16 references indexed in Scilit:
- Papulonecrotic tuberculid in a human immunodeficiency virus type‐1 patient with multidrug‐resistant tuberculosisJournal of the European Academy of Dermatology and Venereology, 2004
- Systemic exposure of pimecrolimus cream 1% and tacrolimus ointment 0.1% in adult patients with moderate to severe atopic dermatitisJournal of the American Academy of Dermatology, 2004
- Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimusInternational Journal of Pharmaceutics, 2004
- Barrier Function of the Skin: “La Raison d'Être” of the EpidermisJournal of Investigative Dermatology, 2003
- Short-Term Glucocorticoid Treatment Compromises Both Permeability Barrier Homeostasis and Stratum Corneum Integrity: Inhibition of Epidermal Lipid Synthesis Accounts for Functional AbnormalitiesJournal of Investigative Dermatology, 2003
- Tacrolimus and pimecrolimus: From clever prokaryotes to inhibiting calcineurin and treating atopic dermatitisJournal of the American Academy of Dermatology, 2002
- Comparison of human skin or epidermis models with human and animal skin in in-vitro percutaneous absorptionInternational Journal of Pharmaceutics, 2001
- Epidermal barrier in disorders of the skinMicroscopy Research and Technique, 1997
- Depletion of stratum corneum intercellular lipid lamellae and barrier function abnormalities after long-term topical corticosteroidsBritish Journal of Dermatology, 1997
- Effect of Sodium Lauryl Sulfate—Induced Skin Irritation on In Vivo Percutaneous Penetration of Four DrugsJournal of Investigative Dermatology, 1991